Caribou Biosciences Inc
NASDAQ:CRBU
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Caribou Biosciences Inc
NASDAQ:CRBU
|
US |
|
N
|
NEXR Technologies SE
XETRA:NXR
|
DE |
|
Wuhan Huazhong Numerical Control Co Ltd
SZSE:300161
|
CN |
|
Ubiquiti Inc
NYSE:UI
|
US |
|
A
|
Arima Real Estate SOCIMI SA
MAD:ARM
|
ES |
|
Major Drilling Group International Inc
TSX:MDI
|
CA |
|
Audax Renovables SA
LSE:0EIB
|
ES |
|
C
|
Centrotec SE
XHAM:CEV
|
DE |
|
Stantec Inc
TSX:STN
|
CA |
|
Bradespar SA
BOVESPA:BRAP4
|
BR |
|
GoPro Inc
NASDAQ:GPRO
|
US |
|
HK Electric Investments Ltd
HKEX:2638
|
HK |
|
H
|
Hunan Gold Corp Ltd
SZSE:002155
|
CN |
|
Gaxos.AI Inc
NASDAQ:GXAI
|
US |
|
S
|
Siemens Gamesa Renewable Energy SA
XETRA:GTQ1
|
ES |
|
Friulchem SpA
MIL:FCM
|
IT |
|
RTL Group SA
XETRA:RRTL
|
LU |
|
Gujarat Alkalies And Chemicals Ltd
NSE:GUJALKALI
|
IN |
|
Csam Health Group AS
OSE:CSAM
|
NO |
|
B
|
Banca Intermobiliare di Investimenti e Gestioni SpA
MIL:BIM
|
IT |
|
A
|
Apollo Healthcare Corp
TSX:AHC
|
CA |
|
Barratt Redrow PLC
LSE:BTRW
|
UK |
|
D
|
Donkeyrepublic Holding A/S
CSE:DONKEY
|
DK |
|
Corporacion Actinver SAB de CV
BMV:ACTINVRB
|
MX |
Caribou Biosciences Inc
Caribou Biosciences, Inc. engages in the development of an internal pipeline of off-the-shelf CAR-T and CAR-NK cell therapies. The company is headquartered in Berkeley, California and currently employs 97 full-time employees. The company went IPO on 2021-07-23. The firm is developing transformative clustered regularly interspaced short palindromic repeats (CRISPR) therapies for patients with devastating diseases. The Company’s CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), enables superior genome-editing precision to develop cell therapies that are specifically engineered for enhanced persistence. The company is advancing a pipeline of allogeneic, or off-the-shelf, chimeric antigen receptor (CAR)-T (CAR-T) and CAR-natural killer (CAR-NK) cell therapies for the treatment of patients with hematologic malignancies and solid tumors. Its lead product candidate, CB-010, is a clinical-stage allogeneic anti-CD19 CAR-T cell therapy with programmed cell death protein 1 (PD-1) removed from the CAR-T cell surface by a genome-edited knockout of the PDCDI gene. The Company’s product candidate also includes CB-011, CB-012 and CB-012.
Caribou Biosciences, Inc. engages in the development of an internal pipeline of off-the-shelf CAR-T and CAR-NK cell therapies. The company is headquartered in Berkeley, California and currently employs 97 full-time employees. The company went IPO on 2021-07-23. The firm is developing transformative clustered regularly interspaced short palindromic repeats (CRISPR) therapies for patients with devastating diseases. The Company’s CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), enables superior genome-editing precision to develop cell therapies that are specifically engineered for enhanced persistence. The company is advancing a pipeline of allogeneic, or off-the-shelf, chimeric antigen receptor (CAR)-T (CAR-T) and CAR-natural killer (CAR-NK) cell therapies for the treatment of patients with hematologic malignancies and solid tumors. Its lead product candidate, CB-010, is a clinical-stage allogeneic anti-CD19 CAR-T cell therapy with programmed cell death protein 1 (PD-1) removed from the CAR-T cell surface by a genome-edited knockout of the PDCDI gene. The Company’s product candidate also includes CB-011, CB-012 and CB-012.
